Laboratorios Richmond SACIF Cash Flow Conversion Efficiency
Laboratorios Richmond SACIF cash flow conversion efficiency. Based on the latest financial reports, Laboratorios Richmond SACIF (RICH) has a cash flow conversion efficiency ratio of 0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AR$202.02 Million ≈ $146.18K USD) by net assets (AR$72.73 Billion ≈ $52.63 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Laboratorios Richmond SACIF (2006–2024)
Cash flow conversion efficiency of Laboratorios Richmond SACIF from 2006 to 2024. This chart illustrates how Laboratorios Richmond SACIF's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Laboratorios Richmond SACIF for real-time trading data and today's change.
Laboratorios Richmond SACIF Cash Flow Conversion Ratio Explained
Laboratorios Richmond SACIF cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Laboratorios Richmond SACIF Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Laboratorios Richmond SACIF ranked by their cash flow conversion efficiency. Also see Laboratorios Richmond SACIF (RICH) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hai Kwang Enterprise Corp
TW:2038
|
0.183x |
|
Deneb Investments Ltd
JSE:DNB
|
0.147x |
|
DCC plc
LSE:DCC
|
0.011x |
|
TEKNA HOLDING ASA NK 2
F:8VB
|
0.062x |
|
Internet Thailand Public Company Limited
BK:INET
|
-1.925x |
|
LENSAR Inc
NASDAQ:LNSR
|
-0.009x |
|
Lion Finance Group PLC
LSE:BGEO
|
0.060x |
|
Tycoons Group Enterprise Co Ltd
TW:2022
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Laboratorios Richmond SACIF (2006–2024)
The table below shows the annual cash flow conversion efficiency of Laboratorios Richmond SACIF from 2006 to 2024. Review cash generation quality of Laboratorios Richmond SACIF to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AR$65.35 Billion ≈ $47.29 Million |
AR$5.62 Billion ≈ $4.07 Million |
0.086x | +194.63% |
| 2023-12-31 | AR$49.98 Billion ≈ $36.17 Million |
AR$-4.54 Billion ≈ $-3.29 Million |
-0.091x | +78.32% |
| 2022-12-31 | AR$10.22 Billion ≈ $7.39 Million |
AR$-4.29 Billion ≈ $-3.10 Million |
-0.419x | -131.00% |
| 2021-12-31 | AR$5.38 Billion ≈ $3.89 Million |
AR$7.27 Billion ≈ $5.26 Million |
1.353x | +2622.42% |
| 2020-12-31 | AR$3.38 Billion ≈ $2.45 Million |
AR$-181.33 Million ≈ $-131.21K |
-0.054x | -193.08% |
| 2019-12-31 | AR$2.10 Billion ≈ $1.52 Million |
AR$121.02 Million ≈ $87.57K |
0.058x | +135.14% |
| 2018-12-31 | AR$1.11 Billion ≈ $803.87K |
AR$-182.16 Million ≈ $-131.81K |
-0.164x | -1109.58% |
| 2017-12-31 | AR$688.05 Million ≈ $497.88K |
AR$11.18 Million ≈ $8.09K |
0.016x | +183.82% |
| 2016-12-31 | AR$189.46 Million ≈ $137.09K |
AR$-3.67 Million ≈ $-2.66K |
-0.019x | +92.67% |
| 2015-12-31 | AR$96.12 Million ≈ $69.55K |
AR$-25.42 Million ≈ $-18.40K |
-0.264x | -477.45% |
| 2011-12-31 | AR$50.10 Million ≈ $36.26K |
AR$3.51 Million ≈ $2.54K |
0.070x | -62.15% |
| 2010-12-31 | AR$44.82 Million ≈ $32.43K |
AR$8.30 Million ≈ $6.00K |
0.185x | +694.54% |
| 2009-12-31 | AR$53.73 Million ≈ $38.88K |
AR$1.25 Million ≈ $905.95 |
0.023x | -95.41% |
| 2007-12-31 | AR$13.25 Million ≈ $9.59K |
AR$6.73 Million ≈ $4.87K |
0.508x | -69.41% |
| 2006-12-31 | AR$7.75 Million ≈ $5.61K |
AR$12.87 Million ≈ $9.31K |
1.661x | -- |
About Laboratorios Richmond SACIF
Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs … Read more